Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
CDNA - Caredx Inc
$88.15
1.32(1.52%)9:00:01 PM 1/15/2021
CareDx, Inc., a precision medicine company, discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and solid organs. In addition, it offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a solution for use in transplantation diagnostic testing. Further, the company provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI and Waitlist Management solutions. It offers its products directly to customers, as well as through third-party distributors. The company has a license agreement with Illumina, Inc. for the development, commercialization, and distribution of next generation sequencing product line for use in transplantation diagnostic testing; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
Stock Chart

Summary:

  • Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
  • RSI is at a high level of 79. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 0.9. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
Peers

Stock news

    01/11/2021CDNA
    CareDx Reports Preliminary Fourth Quarter and Full Year 2020 Results

    SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported preliminary financial results for the fourth quarter and full year ended December 31, 2020. Preliminary revenue for the three months ended December 31, 2020 is expected to be between $58.4 mil...

    01/8/2021CDNA
    CareDx Agrees to Acquire TransChart and Expands EMR Connectivity to Over 90 Centers

    Acquisition will build on CareDx’s digital capabilities and continue deepening the moat with transplant centersSOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has agreed to acquire TransChart LLC, an Ohio-based provider of electronic hea...

    01/8/2021CDNA
    CareDx Transplant Leadership Showcased at ASTS 2021

    CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transplant Surgeons Digital Winter SymposiumSOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced it will be showcasing new transplant data at the upcoming 21st Annual American S...

    01/7/2021CDNA
    CareDx Announces AlloID and Exclusive Partnership with IDbyDNA

    AlloID is a Transplant Patient-Specific Metagenomic Infectious Disease Test Platform, Furthering CareDx’s Innovation in Multi-Modality Surveillance CareSOUTH SAN FRANCISCO, Calif. and SALT LAKE CITY, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Today, CareDx, the leading partner in transplant care, and IDbyDNA, the company revolutionizing the use of precision metagenomics, announced an exclusive partnership focused on the development of metagenomic infectious disease testing specific to transplant patients...

    01/4/2021CDNA
    CareDx’s AlloSeq HCT Wins Tender for French Stem Cell Transplant Patient Surveillance

    CareDx wins a 2-year competitive tender with the French National Blood Service, Établissement Français du SangSOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that AlloSeq HCT was selected as the primary solution for chimerism monitoring of stem c...

    12/31/2020CDNA
    The Zacks Analyst Blog Highlights: MACOM Tech, CrowdStrike, Zscaler, CareDx and Medifast

    The Zacks Analyst Blog Highlights: MACOM Tech, CrowdStrike, Zscaler, CareDx and Medifast